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From mesothelioma to
cardiovascular protection via the
phosphoinositide-3 kinase pathway:
A new vista in cardiothoracic
surgery
To the Editor:
We read with interest the article by Rascoe
and colleagues1 on the role of tyrosine kinase
receptors and the phosphoinositide-3 kinase
(PI3K) pathway in mesothelioma. The au-
thors demonstrated differential involvement
of 3 growth factor (GF) receptors—epider-
mal growth factor (EGF), insulin-like growth
factor (IGF), and platelet-derived growth fac-
tor (PDGF) receptors—in PI3K-mediated
survival of the malignant mesothelioma cells.TSurvival of many cells under stress, par-
ticularly of myocytes, is dependent on PI3K
pathway activation.2 It is not often appreci-
ated, however, that the PI3K pathway can
be activated not only via tyrosine kinase
receptors by GFs, but also via toll-like re-
ceptor by heat shock protein, bacterial li-
popolysaccharide, and by tumor necrosis
factor (Figure 1). Although the precise
molecular mechanisms by which the GF
receptors interact with PI3K pathway are
unknown, they appear to have different
properties. For example, PDGF appears to
play a crucial role in the pathogenesis of
atherosclerosis.3 We agree with Rascoe
and colleagues that PDGF receptor inhibi-
tion does not negatively affect cellular sur-
vival. In fact, PDGF inhibition results in
significant reduction in oxidative stress3
and is observed after ischemic precondi-
tioning.4 Indeed, we have previously dem-
onstrated that intravenous infusion of IGF
improves oxygen transport by reducing ox-
ygen consumption as well as increasing
cardiac output and oxygen delivery after
ischemia-reperfusion (IR) injury.5 Further-ar
he Journal of Thoracic and Cardiovascularmore, cardiovascular protection from IR
injury is abrogated when PI3K pathway is
inhibited by LY294002.2 Thus, systemic
inhibition of IGF or PI3K may result in
detrimental clinical side effects.
While local inhibition of PI3K signaling
either directly or via EGF receptor inhibition
may appear a promising treatment for me-
sothelioma, it is possible that sustained sys-
temic inhibition of PI3K, either directly by
LY294002 or indirectly via tyrosine kinase
receptor inhibition, could lead to rapid pro-
gression of vascular disease and increased
myocardial vulnerability to IR syndromes
in susceptible patients. Whatever the clin-
ical implications of the study by Rascoe
and colleagues might be, any therapeutic
intervention must be applied cautiously and
balanced carefully against potential risks.
In summary, we congratulate Rascoe and
colleagues on their stimulating and thought-
provoking study. It is clear that contemporary
academic cardiothoracic surgery must be per-
formed within the realms of an understand-
ing of the burgeoning field of molecular
gure 1. Schematic of phosphoinositide-3
nase (PI3K) signaling pathway. Activation of
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Letters to the Editorbiology and its relevance to clinical ther-
apy. This is a laudable step along that path.
Igor E. Konstantinov, MD, PhD
Jia Li, MD, PhD
Andrew N. Redington, MD
Department of Cardiovascular Surgery and
Cardiology
Hospital for Sick Children
Toronto, Ontario, Canada
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Reply to the Editor:
We greatly appreciate the kind remarks
and insightful comments by Konstantinov,
Li, and Reddington concerning our recent
manuscript, “Receptor Tyrosine Kinase and
Phosphoinositide-3 Kinase Signaling in Ma-
lignant Mesothelioma.”
Although constitutive activation of the
PI3K/Akt pathway has been demonstrated
in a number of solid malignancies,
its importance is certainly not limited to
neoplastic cells. In fact, Akt signaling en-
hances vital cellular processes such as gly-
cogen synthesis and nitric oxide produc-
tion. LY294002 is a lead compound in
the development of PI3K inhibitors and is
not available for human trials. However,
we believe that further drug development
could possibly produce a compound with
acceptable toxicity and therapeutic poten-
tial in oncology. We agree that any new
scular Surgery ● February 2006interventions must be applied with caution
in the context of a controlled trial.
Similarly, inhibitors of the insulin-like
growth factor receptor are still in the de-
velopmental phase. While such compounds
have potential as antineoplastic agents, there
is also the potential for toxic effects such as
the development of endocrinopathies. How-
ever, inhibitors of receptor tyrosine kinases
such as epidermal growth factor receptor
(Iressa, Tarceva) and platelet-derived growth
factor receptor (Gleevec) are currently used
in the treatment of solid and hematologic
malignant tumors with acceptable side ef-
fect profiles.
We again thank Konstantinov, Li, and
Reddington for their interest in our work. It
is clear that an understanding of molecular
mechanisms will be requisite for contem-
porary clinicians, particularly those treat-
ing cardiovascular and oncologic disease.
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